StockData
Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc. (ARCT) stock

ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3010% below fair value
$7.97−0.34 (-4.09%)

Close on Nov 17, 2026Market cap $226.53MP/E –Yield –

Arcturus Therapeutics cash

Cash and short-term investments held at the end of each period.

Arcturus Therapeutics's cash was $191.48M at Jun 30, 2026. For fiscal 2025 it was $230.91M, down 21.4% from the year before. The highest annual figure on record is $463.00M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$230.91M-21.4%
FY2024Dec 31, 2024$293.91M+0.7%
FY2023Dec 31, 2023$292.01M-25.9%
FY2022Dec 31, 2022$393.98M+5.7%
FY2021Dec 31, 2021$372.57M-19.5%
FY2020Dec 31, 2020$463.00M+548.9%
FY2019Dec 31, 2019$71.35M+93.8%
FY2018Dec 31, 2018$36.82M+45.9%
FY2017Dec 31, 2017$25.24M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$191.48M-2.5%
Q1 FY2026Mar 31, 2026$211.38M-2.6%
Q4 FY2025Dec 31, 2025$230.91M-21.4%
Q3 FY2025Sep 30, 2025$180.36M-24.0%
Q2 FY2025Jun 30, 2025$196.47M-24.5%
Q1 FY2025Mar 31, 2025$216.95M-24.8%
Q4 FY2024Dec 31, 2024$293.91M+0.7%
Q3 FY2024Sep 30, 2024$237.18M-24.0%
Q2 FY2024Jun 30, 2024$260.33M-19.5%
Q1 FY2024Mar 31, 2024$288.40M-12.1%
Q4 FY2023Dec 31, 2023$292.01M-25.9%
Q3 FY2023Sep 30, 2023$311.92M+31.2%
Q2 FY2023Jun 30, 2023$323.47M+14.1%
Q1 FY2023Mar 31, 2023$327.94M+2.6%
Q4 FY2022Dec 31, 2022$393.98M+5.7%
Q3 FY2022Sep 30, 2022$237.68M-42.6%
Q2 FY2022Jun 30, 2022$283.49M-34.6%
Q1 FY2022Mar 31, 2022$319.68M-31.5%
Q4 FY2021Dec 31, 2021$372.57M-19.5%
Q3 FY2021Sep 30, 2021$413.88M+34.8%
Q2 FY2021Jun 30, 2021$433.57M+218.5%
Q1 FY2021Mar 31, 2021$466.84M+685.0%
Q4 FY2020Dec 31, 2020$463.00M+548.9%
Q3 FY2020Sep 30, 2020$307.02M+313.9%
Q2 FY2020Jun 30, 2020$136.11M+143.8%
Q1 FY2020Mar 31, 2020$59.47M+90.5%
Q4 FY2019Dec 31, 2019$71.35M+93.8%
Q3 FY2019Sep 30, 2019$74.17M+144.5%
Q2 FY2019Jun 30, 2019$55.84M+90.4%
Q1 FY2019Mar 31, 2019$31.22M+23.7%
Q4 FY2018Dec 31, 2018$36.82M–
Q3 FY2018Sep 30, 2018$30.33M–
Q2 FY2018Jun 30, 2018$29.32M–
Q4 FY2017Dec 31, 2017$25.24M–

More Arcturus Therapeutics figures

See a number that looks wrong?